<p>PureTech Health PLC 赞助的 ADR (NASDAQ:PRTC - 获取免费报告) 在三月份的空头头寸大幅增加。截至 3 月 31 日，空头头寸总计为 14,823 股，比 3 月 15 日的 11,335 股增加了 30.8%。根据每日平均交易量 3,250 股，目前的空头头寸比率为 4.6 天。公司约有 0.1% 的股份被做空。</p>
<p>获取 <strong>PureTech Health</strong> 的提醒：</p>
<h2>对 PureTech Health 的对冲基金看法</h2>
<p>一家对冲基金最近增加了对 PureTech Health 股票的持股。根据该公司在最近向 SEC 提交的 13F 文件，Pentwater Capital Management LP 在第三季度将其在 PureTech Health PLC 赞助的 ADR (NASDAQ:PRTC - 免费报告) 的持股增加了 50.0%。该机构投资者在季度内购买了额外的 25,000 股后，持有 75,000 股公司的股票。根据其最近向 SEC 提交的文件，Pentwater Capital Management LP 持有的 PureTech Health 股票价值为 1,388,000 美元，占公司股份的 0.31%。机构投资者持有公司 0.04% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>另外，Weiss Ratings 在 1 月 22 日的报告中重申了对 PureTech Health 股票的 &#34;卖出 (d)&#34; 评级。根据 MarketBeat.com 的数据，一名股票研究分析师对该股票给予了卖出评级，目前该公司的平均评级为 &#34;卖出&#34;。</p>
<p><strong>查看我们关于 PureTech Health 的最新报告</strong></p>
<h2>PureTech Health 股票上涨 2.0%</h2>
<p>周三，PRTC 股票上涨 0.36 美元，达到 18.23 美元。该股票交易了 3,250 股，较其平均交易量 4,112 股有所减少。PureTech Health 的 52 周低点为 14.50 美元，52 周高点为 19.92 美元。该公司的 50 日移动平均价格为 16.86 美元，200 日移动平均价格为 17.29 美元。</p>
<h2>关于 PureTech Health</h2>
<p>(获取免费报告)</p>
<p>PureTech Health NASDAQ: PRTC 是一家临床阶段的生物治疗公司，专注于在免疫学、炎症、肿瘤学和神经科学领域创造和开发首创药物。该公司通过在内部孵化项目并将选定资产推进为独立的、创造价值的实体来运营。其内部管道包括多个针对纤维化疾病、实体肿瘤和罕见遗传疾病的临床和临床前候选药物。</p>
<p>PureTech 的专有平台技术涵盖单克隆抗体、小分子和细胞治疗等多种形式。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 PureTech Health</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 PureTech Health 吗？</h2>
<p>在你考虑 PureTech Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买... 而 PureTech Health 并不在名单上。</p>
<p>虽然 PureTech Health 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PRTC

PRTCY

<p>PureTech Health PLC 赞助的 ADR (NASDAQ:PRTC) 在三月份经历了空头头寸的显著增加，上涨了 30.8%，达到 14,823 股。这代表了公司被卖空股份的 0.1%，根据平均每日交易量 3,250 股，覆盖天数比率为 4.6 天。机构投资者 Pentwater Capital Management LP 在第三季度将其持股增加了 50%。分析师对该股票维持 “卖出” 评级，目前交易价格为 18.23 美元，上涨 2.0%</p>

<p>PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 14,823 shares, an increase of 30.8% from the March 15th total of 11,335 shares. Based on an average daily volume of 3,250 shares, the short-interest ratio is currently 4.6 days. Approximately 0.1% of the shares of the company are short sold.</p>
<div class="lb-trans"><p>PureTech Health PLC 赞助的 ADR (NASDAQ:PRTC - 获取免费报告) 在三月份的空头头寸大幅增加。截至 3 月 31 日，空头头寸总计为 14,823 股，比 3 月 15 日的 11,335 股增加了 30.8%。根据每日平均交易量 3,250 股，目前的空头头寸比率为 4.6 天。公司约有 0.1% 的股份被做空。</p>
</div><p>Get <strong>PureTech Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>PureTech Health</strong> 的提醒：</p>
</div><h2>Hedge Funds Weigh In On PureTech Health</h2>
<div class="lb-trans"><h2>对 PureTech Health 的对冲基金看法</h2>
</div><p>A hedge fund recently raised its stake in PureTech Health stock. Pentwater Capital Management LP grew its holdings in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - Free Report) by 50.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 75,000 shares of the company's stock after buying an additional 25,000 shares during the quarter. Pentwater Capital Management LP owned 0.31% of PureTech Health worth $1,388,000 as of its most recent filing with the SEC. Institutional investors own 0.04% of the company's stock.</p>
<div class="lb-trans"><p>一家对冲基金最近增加了对 PureTech Health 股票的持股。根据该公司在最近向 SEC 提交的 13F 文件，Pentwater Capital Management LP 在第三季度将其在 PureTech Health PLC 赞助的 ADR (NASDAQ:PRTC - 免费报告) 的持股增加了 50.0%。该机构投资者在季度内购买了额外的 25,000 股后，持有 75,000 股公司的股票。根据其最近向 SEC 提交的文件，Pentwater Capital Management LP 持有的 PureTech Health 股票价值为 1,388,000 美元，占公司股份的 0.31%。机构投资者持有公司 0.04% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Separately, Weiss Ratings restated a &#34;sell (d)&#34; rating on shares of PureTech Health in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 1 月 22 日的报告中重申了对 PureTech Health 股票的 &#34;卖出 (d)&#34; 评级。根据 MarketBeat.com 的数据，一名股票研究分析师对该股票给予了卖出评级，目前该公司的平均评级为 &#34;卖出&#34;。</p>
</div><p><strong>Check Out Our Latest Report on PureTech Health</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 PureTech Health 的最新报告</strong></p>
</div><h2>PureTech Health Trading Up 2.0%</h2>
<div class="lb-trans"><h2>PureTech Health 股票上涨 2.0%</h2>
</div><p>PRTC traded up $0.36 on Wednesday, hitting $18.23. 3,250 shares of the stock traded hands, compared to its average volume of 4,112. PureTech Health has a 52 week low of $14.50 and a 52 week high of $19.92. The business has a fifty day moving average price of $16.86 and a two-hundred day moving average price of $17.29.</p>
<div class="lb-trans"><p>周三，PRTC 股票上涨 0.36 美元，达到 18.23 美元。该股票交易了 3,250 股，较其平均交易量 4,112 股有所减少。PureTech Health 的 52 周低点为 14.50 美元，52 周高点为 19.92 美元。该公司的 50 日移动平均价格为 16.86 美元，200 日移动平均价格为 17.29 美元。</p>
</div><h2>About PureTech Health</h2>
<div class="lb-trans"><h2>关于 PureTech Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>PureTech Health NASDAQ: PRTC is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.</p>
<div class="lb-trans"><p>PureTech Health NASDAQ: PRTC 是一家临床阶段的生物治疗公司，专注于在免疫学、炎症、肿瘤学和神经科学领域创造和开发首创药物。该公司通过在内部孵化项目并将选定资产推进为独立的、创造价值的实体来运营。其内部管道包括多个针对纤维化疾病、实体肿瘤和罕见遗传疾病的临床和临床前候选药物。</p>
</div><p>PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.</p>
<div class="lb-trans"><p>PureTech 的专有平台技术涵盖单克隆抗体、小分子和细胞治疗等多种形式。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than PureTech Health</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 PureTech Health</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PureTech Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 PureTech Health 吗？</h2>
</div><p>Before you consider PureTech Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 PureTech Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买... 而 PureTech Health 并不在名单上。</p>
</div><p>While PureTech Health currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 PureTech Health 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

PureTech Health PLC 赞助的美国存托凭证（NASDAQ:PRTC）在三月份的空头头寸增加了 30.8%